Literature DB >> 34427906

Hepatic Clearance of Cell-Free DNA: Possible Impact on Early Metastasis Diagnosis.

Sonia Khier1,2, Peter B Gahan3.   

Abstract

Circulating DNA in the bloodstream has been studied since the 1940s, leading to its identification as a possible early marker for the presence of a primary tumor. Recently, it has been more successfully employed in liquid biopsies to determine the early presence of a metastatic tumor arising after chemotherapy, radiotherapy, and surgery. The appearance of such circulating tumor DNA permits the identification of the metastatic tumor before it is detected by either palpation or radiological analysis. Nevertheless, the liquid biopsy may possibly be affected by the removal of circulating tumor DNA via the kidneys and spleen as it is released. Furthermore, the liver removal of cell-free DNA has not yet been considered to be involved in this process. Here, we review the literature on the removal of free single- and double-stranded DNA and nucleosomal, vesicular, and exosomal DNA via the liver and examine its possible impact on circulating DNA levels. The removal of all forms of DNA by the liver, together with that removed by the kidneys and spleen, may delay the timing of positive results from liquid biopsies.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34427906     DOI: 10.1007/s40291-021-00554-2

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  44 in total

1.  Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

Authors:  Isaac Garcia-Murillas; Neha Chopra; Iñaki Comino-Méndez; Matthew Beaney; Holly Tovey; Rosalind J Cutts; Claire Swift; Divya Kriplani; Maria Afentakis; Sarah Hrebien; Giselle Walsh-Crestani; Peter Barry; Stephen R D Johnston; Alistair Ring; Judith Bliss; Simon Russell; Abigail Evans; Anthony Skene; Duncan Wheatley; Mitch Dowsett; Ian E Smith; Nicholas C Turner
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777

2.  Cancer drug resistance needs urgent attention, says research chief.

Authors:  Rebecca Coombes
Journal:  BMJ       Date:  2019-04-26

3.  Non-invasive prenatal testing for fetal aneuploidy: charting the course from clinical validity to clinical utility.

Authors:  L Hui
Journal:  Ultrasound Obstet Gynecol       Date:  2013-01       Impact factor: 7.299

Review 4.  Use of Circulating Tumor DNA for Cancer Immunotherapy.

Authors:  Alexandra Snyder; Michael P Morrissey; Matthew D Hellmann
Journal:  Clin Cancer Res       Date:  2019-07-08       Impact factor: 12.531

5.  Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.

Authors:  Barzin Y Nabet; Mohammad S Esfahani; Everett J Moding; Emily G Hamilton; Jacob J Chabon; Hira Rizvi; Chloe B Steen; Aadel A Chaudhuri; Chih Long Liu; Angela B Hui; Diego Almanza; Henning Stehr; Linda Gojenola; Rene F Bonilla; Michael C Jin; Young-Jun Jeon; Diane Tseng; Cailian Liu; Taha Merghoub; Joel W Neal; Heather A Wakelee; Sukhmani K Padda; Kavitha J Ramchandran; Millie Das; Andrew J Plodkowski; Christopher Yoo; Emily L Chen; Ryan B Ko; Aaron M Newman; Matthew D Hellmann; Ash A Alizadeh; Maximilian Diehn
Journal:  Cell       Date:  2020-10-01       Impact factor: 41.582

6.  Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.

Authors:  Qu Zhang; Jia Luo; Han Si; Shaad E Abdullah; Brandon W Higgs; Todd Hembrough; Song Wu; Chen Gao; Wenjing Xu; Phillip A Dennis; Michiel S van der Heijden; Neil H Segal; Jamie E Chaft; J Carl Barrett; Matthew D Hellmann
Journal:  Cancer Discov       Date:  2020-08-14       Impact factor: 39.397

7.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Authors:  Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Sci Transl Med       Date:  2016-07-06       Impact factor: 17.956

Review 8.  Origins, structures, and functions of circulating DNA in oncology.

Authors:  A R Thierry; S El Messaoudi; P B Gahan; P Anker; M Stroun
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

9.  Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer.

Authors:  Mathilde Borg Houlberg Thomsen; Iver Nordentoft; Philippe Lamy; Søren Vang; Line Reinert; Christophe Kamungu Mapendano; Søren Høyer; Torben F Ørntoft; Jørgen Bjerggaard Jensen; Lars Dyrskjøt
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

10.  Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.

Authors:  Xingdong Chen; Jeffrey Gole; Athurva Gore; Qiye He; Ming Lu; Jun Min; Ziyu Yuan; Xiaorong Yang; Yanfeng Jiang; Tiejun Zhang; Chen Suo; Xiaojie Li; Lei Cheng; Zhenhua Zhang; Hongyu Niu; Zhe Li; Zhen Xie; Han Shi; Xiang Zhang; Min Fan; Xiaofeng Wang; Yajun Yang; Justin Dang; Catie McConnell; Juan Zhang; Jiucun Wang; Shunzhang Yu; Weimin Ye; Yuan Gao; Kun Zhang; Rui Liu; Li Jin
Journal:  Nat Commun       Date:  2020-07-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.